Mimedx (MDXG) Share-based Compensation (2011 - 2026)
Mimedx (MDXG) reported Share-based Compensation of $1.9 million for Q1 2026, down 22.66% on a YoY basis from $2.5 million in Q1 2025, and up 3627.45% sequentially from $51000.0 in Q4 2025.
Mimedx (MDXG) Share-based Compensation (2011 - 2026) Analysis & Trends
Mimedx (MDXG) has 16 years of Share-based Compensation data on file, last reported at $1.9 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation fell 22.66% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.6 million (up 237.42% YoY), and the FY2025 full-year result was $3.1 million, up 18.06% from the prior year.
- Share-based Compensation climbed to $1.9 million in Q1 2026, from $51000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $6.6 million in Q2 2025 to a low of -$5.9 million in Q3 2025.
- A 5-year average of $2.0 million and a median of $2.4 million in 2022 frame the typical range for Share-based Compensation.
- Peak annual rise in Share-based Compensation reached 456.5% in 2025, while the deepest fall reached 5506.36% in 2025.
- Tracing MDXG's Share-based Compensation over 5 years: stood at $530000.0 in 2022, then jumped by 727.92% to $4.4 million in 2023, then slumped by 99.32% to $30000.0 in 2024, then surged by 70.0% to $51000.0 in 2025, then jumped by 3627.45% to $1.9 million in 2026.
- Business Quant data shows MDXG's Share-based Compensation at $1.9 million in Q1 2026, $51000.0 in Q4 2025, and -$5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Mimedx | 615.09 Mn | 455.31 Mn | 41.62 Mn | 1.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.90 Mn |
| Mar 31, 2026 | 1.90 Mn |
| Dec 31, 2025 | 51,000.00 |
| Dec 31, 2025 | 51,000.00 |
| Sep 30, 2025 | -5.95 Mn |
| Sep 30, 2025 | -5.95 Mn |
| Jun 30, 2025 | 6.56 Mn |
| Jun 30, 2025 | 6.56 Mn |
| Mar 31, 2025 | 2.46 Mn |
| Mar 31, 2025 | 2.46 Mn |
| Dec 31, 2024 | 30,000.00 |
| Dec 31, 2024 | 30,000.00 |
| Sep 30, 2024 | 110,000.00 |
| Sep 30, 2024 | 110,000.00 |
| Jun 30, 2024 | -1.84 Mn |
| Jun 30, 2024 | -1.84 Mn |
| Mar 31, 2024 | 4.34 Mn |
| Mar 31, 2024 | 4.34 Mn |
| Sep 30, 2023 | 4.39 Mn |
| Sep 30, 2023 | 4.39 Mn |